Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila
- 28 July 2004
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 23 (8) , 650-652
- https://doi.org/10.1007/s10096-004-1152-2
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumoniaClinical Microbiology & Infection, 2003
- Telithromycin in the treatment of community-acquired pneumonia: a pooled analysisRespiratory Medicine, 2003
- EFFICACY AND TOLERABILITY OF ONCE‐DAILY ORAL THERAPY WITH TELITHROMYCIN COMPARED WITH TROVAFLOXACIN FOR THE TREATMENT OF COMMUNITY‐ACQUIRED PNEUMONIA IN ADULTSInternational Journal Of Clinical Practice, 2003
- Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired PneumoniaInfection, 2002
- New outbreak of legionnaires' disease in the United KingdomBMJ, 2002
- Efficacy and Safety of Telithromycin in Community-acquired PneumoniaCurrent Medical Research and Opinion, 2002
- Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogensJournal of Antimicrobial Chemotherapy, 2001
- Lung concentrations of telithromycin after oral dosing.Journal of Antimicrobial Chemotherapy, 2001
- TelithromycinDrugs, 2001
- Interactions between HMR 3647, a New Ketolide, and Human Polymorphonuclear NeutrophilsAntimicrobial Agents and Chemotherapy, 1998